[1]
Palumbo, M.O.; Kavan, P.; Miller, Jr., W.H.; Panasci, L.; Assouline, S.; Johnson, N.; Cohen, V.; Patenaude, F.; Pollak, M.; Jagoe, R.T.; Batist, G. Systemic cancer therapy: Achievements and challenges that lie ahead. Front. Pharmacol., 2013, 4, 57.
[2]
Roubille, C.; Richer, V.; Starnino, T.; McCourt, C.; McFarlane, A.; Fleming, P.; Siu, S.; Kraft, J.; Lynde, C.; Pope, J.; Gulliver, W.; Keeling, S.; Dutz, J.; Bessette, L.; Bissonnette, R.; Haraoui, B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann. Rheum. Dis., 2015, 74, 480-489.
[3]
Deyab, G.; Hokstad, I.; Whist, J.E.; Smastuen, M.C.; Agewall, S.; Lyberg, T.; Ronda, N.; Mikkelsen, K.; Hjeltnes, G.; Hollan, I. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res. Ther., 2017, 19, 232-244.
[4]
Montaudie, H.; Sbidian, E.; Paul, C.; Maza, A.; Gallini, A.; Aractingi, S.; Aubin, F.; Bachelez, H.; Cribier, B.; Joly, P.; Jullien, D.; Le Maitre, M.; Misery, L.; Richard, M-A.; Ortonne, J-P. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J. Eur. Acad. Dermatol. Venereol., 2011, 25(2), 1-33.
[5]
Youm, I.; West, M.B.; Li, W.; Du, X.; Ewert, D.L.; Kopke, R.D. siRNA-loaded biodegradable nanocarriers for therapeutic MAPK1 silencing against cisplatin-induced ototoxicity. Int. J. Pharm., 2017, 528, 611-623.
[6]
Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol., 2014, 740, 364-378.
[7]
Aravindan, S.; Natarajan, M.; Herman, T.S.; Awasthi, V.; Aravindan, N. Molecular basis of ‘hypoxic’ breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. Radiat. Oncol., 2013, 8, 46.
[8]
Huq, F.; Yu, J.Q.; Beale, P.; Chan, C.; Arzuman, L.; Nessa, M.U.; Mazumder, M.E. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res., 2014, 34(1), 541-545.
[9]
Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M.F.; Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Shantha Kumara, H.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Vander Heiden, M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35, S276-S304.
[10]
Fleming, F.F.; Yao, L.; Ravikumar, P.C.; Funk, L.; Shook, B.C. Nitrile-containing pharmaceuticals: Efficacious roles of the nitrile pharmacophore. J. Med. Chem., 2010, 53, 7902-7917.
[11]
Sun, Z.; Zhang, K.; Chen, C.; Wu, Y.; Tang, Y.; Georgiev, M.I.; Zhang, X.; Lin, M.; Zhou, M. Biosynthesis and regulation of cyanogenic glycoside production in forage plants. Appl. Microbiol. Biotechnol., 2018, 102, 9-16.
[12]
Jinih, M.; Relihan, N.; Corrigan, M.A.; O’Reilly, S.; Redmond, H.P. Extended adjuvant endocrine therapy in breast cancer: Evidence and update. Breast J., 2017, 23(6), 694-705.
[13]
Alemrayat, B.; Elhissi, A.; Younes, H.M. Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy. Pharm. Dev. Technol., 2019, 24(2), 235-242.
[14]
Liu, C.; Armstrong, C.M.; Lou, W.; Lombard, A.P.; Cucchiara, V.; Gu, X.; Yang, J.C.; Nadiminty, N.; Pan, C.X.; Evans, C.P.; Gao, A.C. Niclosamide and bicalutamide combination treatment overcomes enzalutamide and bicalutamide resistant prostate cancer. Mol. Cancer Ther., 2017, 16, 1521-1530.
[15]
Langdon, S.P.; Gourley, C.; Gabra, H.; Stanley, B. Endocrine therapy in epithelial ovarian cancer. Expert Rev. Anticancer Ther., 2017, 17(2), 109-117.
[16]
Reis, L.O.; Zani, E.L.; Garcia-Perdomo, H.A. Estrogen therapy in patients with prostate cancer: a contemporary systematic review. Int. Urol. Nephrol., 2018, 50, 993-1003.
[17]
Park, S.G.; Kim, S.H.; Kim, K.Y.; Yu, S.N.; Choi, H.D.; Kim, Y.W.; Nam, H.W.; Seo, Y.K.; Ahn, S.C. Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells. Pharmacol. Rep., 2017, 69, 90-96.
[18]
Gee, M.S.; Kang, S.B. ·Kim, N.; Choi, J.; Kim, N.J.; Kim, B.J.; Inn, K.S.; Lee, J.K. Bardoxolone methyl suppresses Hepatitis B virus large surface protein variant W4P-related carcinogenesis and hepatocellular carcinoma cell proliferation via the inhibition of signal transducer and activator of transcription 3 signaling. Pharmacology, 2018, 102, 105-113.
[19]
Shanmugam, M.K.; Dai, X.; Kumar, A.P.; Tan, B.K.; Sethi, G.; Bishayee, A. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett., 2014, 346, 206-216.
[20]
Wang, Y.Y.; Yang, Y.X.; Zhe, H.; He, Z.X.; Zhou, S.F. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: An update on its pharmacokinetic and pharmacodynamic properties. Drug Des. Devel. Ther., 2014, 8, 2075-2088.
[21]
Wang, Y.Y.; Zhe, H.; Zhao, R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol. Cancer, 2014, 13, 30-38.
[22]
Liby, K.T.; Sporn, M.B. Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev., 2012, 64, 972-1003.
[23]
Favaloro, F.G.; Honda, T.; Honda, Y.; Gribble, G.W.; Suh, N.; Risingsong, R.; Sporn, M.B. Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: A novel class of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem., 2002, 45(22), 4801-4805.
[24]
Honda, T.; Sundararajan, C.; Yoshizawa, H.; Su, X.; Honda, Y.; Liby, K.T.; Sporn, M.B.; Gribble, G.W. Novel tricyclic compounds having acetylene groups at C8a and cyano enones in rings A and C: Highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem., 2007, 50, 1731-1734.
[25]
Honda, T.; Yoshizawa, H.; Sundararajan, C.; David, E.; Lajoie, M.J.; Favaloro, Jr. F.G.; Janosik, T.; Su, X.; Honda, Y.; Roebuck, B.D.; Gribble, G.W. Tricyclic compounds containing non-enolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents. J. Med. Chem., 2011, 54, 1762-1778.
[26]
Dinkova-Kostova, A.T.; Talalay, P.; Sharkey, J.; Zhang, Y.; Holtzclaw, W.D.; Wang, X.J.; David, E.; Schiavoni, K.H.; Finlayson, S.; Dale, D.F.; Mierke, F.; Honda, T. An exceptionally potent inducer of cytoprotective enzymes: Elucidation of the structural features that determine inducer potency and reactivity with Keap1. J. Biol. Chem., 2010, 285, 33747-33755.
[27]
Kostov, R.V.; Knatko, E.V.; McLaughlin, L.A.; Henderson, C.J.; Zheng, S.; Huang, J.T.J.; Tadashi, H.; Dinkova-Kostova, A.T. Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochem. Biophys. Res. Commun., 2015, 465, 402-407.
[28]
Flekhter, O.B.; Tret’yakova, E.V.; Makara, N.S.; Gabdrakhmanova, S.F.; Baschenko, N.Z.; Galin, F.Z.; Zarudii, F.S.; Tolstikov, G.A. Synthesis and antiulcer activity of quinopimaric acid derivatives. Russ. Pharm. Chem. J., 2003, 37, 142-144.
[29]
Kazakova, O.B.; Tret’yakova, E.V.; Smirnova, I.E.; Spirikhin, L.V.; Tolstikov, G.A.; Chudov, I.V.; Bazekin, G.V.; Ismagilova, A.F. The synthesis and anti-inflammatory activity of quinopimaric acid derivatives. Russ. J. Bioorganic Chem., 2010, 36, 257-262.
[30]
Tret’yakova, E.V.; Zakirova, G.F.; Salimova, E.V.; Kukovinets, O.S.; Odinokov, V.N.; Parfenova, L.V. Convenient one-pot synthesis of resin acid Mannich bases as novel anticancer and antifungal agents. Med. Chem. Res., 2018, 27, 2199-2213.
[31]
Tretyakova, E.V.; Smirnova, I.E.; Salimova, E.V.; Odinokov, V.N. Synthesis and antiviral activity of maleopimaric and quinopimaric acids’ derivatives. Bioorg. Med. Chem., 2015, 23, 6543-6550.
[32]
Tret’yakova, E.V.; Smirnova, I.E.; Kazakova, O.B.; Yavorskaya, N.P.; Golubeva, I.S.; Zhukova, O.S.; Pugacheva, R.B.; Apryshko, G.N.; Poroikov, V.V. Synthesis and anticancer activity of quinopimaric and maleopimaric acid’s derivatives. Bioorg. Med. Chem., 2014, 22, 6481-6489.
[33]
Herz, W.; Nair, M.G. Resin acids. XIX. Structure and Stereochemistry of Adducts of Levopimaric Acid with Cyclopentenone and 1-Cyclopentene-3,5-dione. Favorskii reaction of an enedione epoxide. J. Org. Chem., 1969, 34, 4016-4023.
[34]
Bruson, H. Cyanoethylation. Org. React., 1949, 5, 79-135.
[35]
Malik, M.A.; Wani, M.Y.; Al-Thabaiti, S.A.; Shiekh, R.A. Tetrazoles as carboxylic acid isosteres: Chemistry and biology. J. Incl. Phenom. Macrocycl. Chem., 2014, 78, 15-37.
[36]
Grever, M.R.; Schepartz, S.A.; Chabner, B.A. The national cancer institute: cancer drug discovery and development program. Semin. Oncol., 1992, 19, 622-638.
[37]
Monks, A.; Scudiero, D.A.; Skehan, P.; Shoemaker, R.; Paull, K.D.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 1991, 83, 757-766.
[38]
Monks, A.; Scudiero, D.A.; Johnson, G.S.; Paull, K.D.; Sausville, E.A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Des., 1997, 12, 533-541.
[39]
Boyd, M.R.; Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 1995, 34, 91-109.
[40]
Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Natl. Rev., 2006, 6, 813-823.
38
2
1
1